Issue link: https://viewer.e-digitaledition.com/i/394279
IT IS EXTREMELY RARE for an individual with rheumatoid arthritis to have Alzheimer's disease. As a result, Huntington Potter, Ph.D., suspected that cellular abnormalities associated with rheumatoid arthritis prevent Alzheimer's disease. Dr. Potter directed Tim Boyd, Ph.D., M.S.B., Research Associate at the Linda Crnic Institute for Down Syndrome and the University of Colorado School of Medicine Department of Neurology, to investigate further. Dr. Boyd analyzed mouse models with Alzheimer's disease and observed immune cells passing from the bloodstream into the brain. He discovered that as the amyloid plaques — responsible for Alzheimer's disease — grew in size, the number of immune cells decreased. He hypothesized that in high numbers, these immune cells may prevent, and even reverse, the development of amyloid plaque. Dr. Boyd noted that one growth factor — granulocyte-macrophage colony-stimulating factor (GM-CSF) — removed all amyloid plaques within seven days. This growth factor also had a significant impact on cognition — following 14 days of treatment with GM-CSF, mice with Alzheimer's disease showed complete reversal of memory loss and brain damage. "We discovered that GM-CSF not only removes the amyloid plaques, but also creates neural stem cells and protects the neurons surrounding the plaques," Dr. Boyd said. "Basically, it does everything it needs to do to reverse Alzheimer's disease–related damage." To determine whether or not GM-CSF has the same effect on humans with Alzheimer's disease, Dr. Potter and his associates are planning to launch a six-month trial at the Crnic Institute examining use of a medication called Leukine, which contains a synthetic form of GM-CSF, in people with mild-to-moderate Alzheimer's disease. Untangling the Connection Between Arthritis and Alzheimer's individuals with Down syndrome don't develop Alzheimer's disease symptoms, even though they have the characteristic amyloid plaques and tau tangles that occur during Alzheimer's disease development. "Some individuals with Down syndrome do not develop dementia and seem to be immune from the effects of plaques and tangles," Dr. Potter said. "We are currently trying to determine why they are protected from Alzheimer's disease pathology and whether this can be used to prevent typical people from developing Alzheimer's disease- related dementia." Dr. Potter is also involved in other clinical trials. One tests the effects of caffeine, which shields mice with Alzheimer's disease from developing dementia, to see if similar effects may occur in Alzheimer's disease patients. COLLABORATION WITH THE ALZHEIMER'S ASSOCIATION Dr. Potter and Tom Blumenthal, Ph.D., Executive Director of the Crnic Institute, have also launched a joint program with the Alzheimer's Association called the Down Syndrome-Alzheimer's Disease Investigator Program. Together with the Global Down Syndrome Foundation, the program has reviewed hundreds of applications and is funding over $2 million in grants around the world. To learn more about Alzheimer's disease and Down syndrome research, go to globaldownsyndrome.org/alzheimers. TREATING LEUKEMIA BY CONTROLLING B-CELLS B-cells are a type of immune cell that can over- proliferate and reach a damaging state known as B-ALL that may lead to leukemia. Research at the Dana-Farber Cancer Institute at Harvard Medical School found that, in mice, a protein known as HMGN1 that lives on chromosome 21 causes B-cell over-proliferation and, eventually, B-ALL. Their research provides very important new insight into treating B-ALL, and possibly leukemia, in people with Down syndrome. Nature Genetics, April 2014 EDUCATION AND GREEN TEA: GOOD FOR THOSE WITH DOWN SYNDROME DYRK1A, a gene located on chromosome 21 that reduces neuron formation, exists in higher amounts in people with Down syndrome than in typical individuals. However, researcher Mara Dierssen, Group Leader at the Center for Genomic Regulation in Barcelona, Spain, has found that enriched, stimulating learning environments reduce DYRK1A to typical levels and increase neuron formation in mice. She's also found that EGCG, a compound in green tea, has much the same effect in animal models, reducing levels of DYRK1A and improving learning and memory. Neurobiology of Disease, Dec. 2013; Molecular Nutrition & Food Research, Feb. 2014; Neuron Glia Biology, Nov. 2004 WEIGHT LOSS FOR CHILDREN WITH SPECIAL NEEDS To counteract obesity in children with autism, Down syndrome, and other developmental disabilities, researchers at Children's Mercy Hospital in Kansas City enrolled 76 such children in a multidisciplinary weight management program. A combination of lifestyle intervention and healthy diet significantly reduced body mass index, providing possible weight-loss interventions for children with certain disabilities. Journal of Developmental and Behavioral Pediatrics, May 2014 BETTER SLEEP BOOSTS LEARNING Sleep apnea occurs in just 5 percent of typical children but estimates in children with Down syndrome are unclear. A recent study of 8-year-olds in Norway suggests that 59 percent of children with Down syndrome suffer mild to moderate obstructive sleep apnea. Improving the diagnosis in these children could help improve cognition and school performance. International Journal of Pediatric Otorhinolaryngology, July 2014 FALL2014 DOWN SYNDROME WORLD 10 CONTINUED FROM PAGE 8 Dr. Huntington Potter SCIENCE SNPS Continued

